T-Ray Science Announces Results of Annual General Meeting

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 16, 2010) - T-Ray Science, Inc. (TSX VENTURE: THZ) announces that its annual general meeting of shareholders was held on July 15, 2010.

Shareholders elected Joe Biegel, Karen Boodram, Ralph Braun, Thomas Braun, Chris Dennis and Jake Thiessen as directors.

Thomas Braun is T-Ray’s CEO, Ralph Braun is T-Ray’s CFO, Karen Boodram is the President of Biomanna Medical Business Development Consulting, Chris Dennis is the President of Comcare Health Services, Inc. and Dr. Jake Thiessen is the Hallman Director of the School of Pharmacy and the Director of the Health Sciences Campus at the University of Waterloo.

Jamie Weir, who has been a director since August 2009 did not to stand for re-election but will continue to play an advisory role with the Company as needed. Joe Biegel is a new addition to the board. Mr. Biegel is the Vice President of Product Management and Marketing for the Medical Imaging Division of McKesson Provider Technologies.

“Our non-invasive skin cancer detection program has moved forward dramatically with our recently announced Licensing Agreement. Having Mr. Biegel’s expertise in medical imaging on our board at this time will greatly support our product development efforts,” commented Thomas Braun, T-Ray’s CEO. “The management and directors of T-Ray would also like to thank Mr. Weir for his efforts in advancing the Company over the past year.”

Additionally, shareholders approved the appointment of Fernandez Young LLP as the auditors of the Company for the coming year and approved the Company’s new stock option plan.

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company centered on commercialization of an innovative skin cancer detection system for the early diagnosis and treatment of all significant forms of skin cancer. (Including: melanoma, basal cell carcinoma and squamous cell carcinoma).

The Company’s patented imaging and spectroscopy technologies are the foundation for the development of the company’s non-invasive, in vivo skin cancer detection and delineation system. This diagnostic tool will deliver significant clinical impact through improved patient outcomes, and will reduce healthcare costs by eliminating the need for most biopsies. The platform technology is extensible to other forms of cancer including gastro-intestinal and cervical cancers.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of THz based products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.